Literature DB >> 27888881

Central Nervous System Prophylaxis for Aggressive B-cell Lymphoma: Who, What, and When?

Norbert Schmitz1, Maike Nickelsen2, Kerry J Savage3.   

Abstract

Central nervous system (CNS) relapse of aggressive B-cell lymphoma is a rare but serious complication with poor survival. Different approaches have been used to define risks factors for CNS relapse and establish prophylactic measures. Although patients with low or intermediate risk of CNS relapse should not undergo special diagnostic or therapeutic measures, CNS MRI as well as cytology and flow cytometry of the cerebrospinal fluid are suggested for high-risk patients (and patients with testicular involvement) at diagnosis, and prophylactic high-dose methotrexate in patients without proven CNS involvement. Future risk and treatment models may include molecular features and new treatment options. Copyright Â
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  B-cell lymphoma; Central nervous system; Prophylaxis

Mesh:

Substances:

Year:  2016        PMID: 27888881     DOI: 10.1016/j.hoc.2016.07.008

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  2 in total

1.  The Diving Bell and the Butterfly Revisited: A Fatal Case of Locked-in Syndrome in a Man With Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified.

Authors:  Jacqueline N Poston; Russell Dorer; David M Aboulafia
Journal:  Clin Med Insights Blood Disord       Date:  2018-03-26

2.  CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies.

Authors:  Ayed O Ayed; Annalisa Chiappella; Levi Pederson; Betsy R Laplant; Angela Giovanna Congiu; Gianluca Gaidano; Michele Spina; Alessandro Re; Federica Cavallo; Gerardo Musuraca; William R Macon; Thomas Witzig; Umberto Vitolo; Grzegorz S Nowakowski
Journal:  Blood Cancer J       Date:  2018-06-26       Impact factor: 11.037

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.